Literature DB >> 3289950

Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males.

B Ljungberg1, I Nilsson-Ehle.   

Abstract

The pharmacokinetics of ceftazidime have been investigated after single and multiple i.v. doses in 9 young healthy male volunteers and 15 elderly male patients with acute bacterial infections. All subjects had normal, age-correlated glomerular function. Distribution and elimination in young volunteers were unaffected by posture and were similar to what has been reported earlier. In contrast, elderly patients had longer t1/2 beta (3.1 vs 1.9 h), larger AUC (414.0 vs 276.6 h.mg/l), lower total and renal clearances, reduced urinary recovery over 12 h and enlarged Vss. Total serum clearance of ceftazidime was closely correlated with the 51Cr-EDTA clearance. There was no significant change in 51Cr-EDTA clearance after seven days of treatment. A reduction in the dose of beta-lactam antibiotics eliminated by the kidney is advisable in elderly patients with an acute bacterial infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3289950     DOI: 10.1007/bf00614556

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  39 in total

1.  Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males.

Authors:  D F DAVIES; N W SHOCK
Journal:  J Clin Invest       Date:  1950-05       Impact factor: 14.808

2.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

3.  Pharmacokinetics of ceftazidime in normal and uremic subjects.

Authors:  A Leroy; F Leguy; F Borsa; G R Spencer; J P Fillastre; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

4.  Ceftazidime and renal function.

Authors:  K Alestig; B Trollfors; R Andersson; L Olaison; M Suurküla; S R Norrby
Journal:  J Antimicrob Chemother       Date:  1984-02       Impact factor: 5.790

5.  Pharmacokinetics of ceftazidime in patients with renal insufficiency.

Authors:  L S Welage; R W Schultz; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

6.  Comparative pharmacokinetics of ceftazidime and moxalactam.

Authors:  T B Tjandramaga; A Van Hecken; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

7.  Influence of age on the pharmacokinetics of ceftazidime in acutely ill, adult patients.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers.

Authors:  S M Harding; A J Monro; J E Thornton; J Ayrton; M I Hogg
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

9.  Ceftazidime: pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections.

Authors:  K G Naber; F Kees; H Grobecker
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

10.  Is renal function the only determinant in the elimination of ceftazidime?

Authors:  P K Narang; J R Hunter
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct
View more
  7 in total

1.  Population pharmacokinetics of continuous infusion ceftazidime.

Authors:  B C Frame; B F Facca; D P Nicolau; S N Triesenberg
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

2.  Pharmacokinetics of ceftazidime in acutely ill hospitalised elderly patients.

Authors:  M Jonsson; M Walder
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

3.  Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group.

Authors:  A Nyhlén; B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

4.  A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation.

Authors:  Jean Marie Conil; Bernard Georges; Michel Lavit; Jacky Laguerre; Kamram Samii; Georges Houin; Sylvie Saivin
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

5.  Influence of age on the pharmacokinetics of ceftazidime in acutely ill, adult patients.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 6.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

7.  Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction.

Authors:  Bo-Hao Tang; Zheng Guan; Karel Allegaert; Yue-E Wu; Efthymios Manolis; Stephanie Leroux; Bu-Fan Yao; Hai-Yan Shi; Xiao Li; Xin Huang; Wen-Qi Wang; A-Dong Shen; Xiao-Ling Wang; Tian-You Wang; Chen Kou; Hai-Yan Xu; Yue Zhou; Yi Zheng; Guo-Xiang Hao; Bao-Ping Xu; Alison H Thomson; Edmund V Capparelli; Valerie Biran; Nicolas Simon; Bernd Meibohm; Yoke-Lin Lo; Remedios Marques; Jose-Esteban Peris; Irja Lutsar; Jumpei Saito; Jacobus Burggraaf; Evelyne Jacqz-Aigrain; John van den Anker; Wei Zhao
Journal:  Clin Pharmacokinet       Date:  2021-05-27       Impact factor: 5.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.